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1. Introduction 
Despite advances in emergency response and critical care, good neurologic outcome after 
cardiac arrest is difficult to achieve, and interventions during the resuscitation phase and 
treatment within the first hours after the event are crucial. Although recommended by 
organizations such as the American Heart Association (AHA) and the International Liaison 
Committee on Resuscitation (ILCOR), implementation of induced mild therapeutic 
hypothermia for survivors of cardiac arrest in the United States has been slow, at least in 
part, because of the perception that this therapy is technically difficult, especially at the 
community level. In this chapter, we review the pathophysiology, cooling techniques, 
clinical evidence and uses (including costs), and effectiveness of induced mild therapeutic 
hypothermia in adult patients after cardiopulmonary resuscitation, using any cooling 
method applied within six hours of arrest. Neurologic outcome, survival and adverse events 
are the main outcome parameters outlined here. In addition, we also include a discussion of 
the applicability of mild therapeutic hypthermia for both academic health centers and 
community hospitals, as well as areas of uncertainty, guidelines, and recommendations.  
2. Epidemiology of cardiac arrest 
The incidence of out-of-hospital sudden cardiac arrest in industrialized countries is about 62 
cases per 100,000 a year making sudden cardiac arrest a major cause of death in the United 
States amounting to more than 300,000 occurrences of cardiac arrests outside of hospital each 
year (Adler et al, 2011). Resuscitation is attempted on roughly 100,000 of these arrest patients 
but results in only 40,000 patients who survive upon arrival to the hospital (Holzer, 2010). 
Despite advances in emergency medical services the mortality and morbidity associated 
with out-of hospital cardiac arrest is high. In 2006, the National Registry of 
Cardiopulmonary Resuscitation (CPR) published statistics on 19,819 adults and 524 children 
with return of spontaneous circulation after cardiac arrest. The mortality rates were 67% 
among adults and 55% among children (Jacobshagen et al, 2010). Currently, less than half of 
cardiac arrest patients survive to discharge and less than a third of those discharged have a 
good neurologic outcome as defined by the Cerebral Performance Category (CPS) Scale 
(Adler et al, 2011). The cost of caring for patients with poor neurologic function within the 
first six months alone can range anywhere from $10,000 to $300,000, with an increasing 
morbidity generally associated with increasing cost (Merchant et al, 2009). 
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3. Pathophysiology of induced mild therapeutic hypothermia  
The brain receives approximately 15% of the human resting cardiac output despite 
comprising 1-2% of our total body weight, illustrating the high metabolic demands 
associated with the brain. During cardiac arrest the blood supply is interrupted leading to 
global cerebral ischemia. 
Ischemic events are especially detrimental to the brain and are a major cause of morbidity in 
cardiac arrest survivors. Areas such as the hippocampus, neocortex, cerebellum, corpus 
striatium, and thalamus are the most vulnerable to global ischemia. Necrosis and apoptosis 
have both been reported in cardiac arrest victims and it still is unclear the extent to which 
each of these processes contribute to neuronal cell death. The brain is damaged through an 
ischemic cascade of events occurring on a time scale of minutes-to-days after cardiac arrest 
and is summarized below.  
A lack of oxygen hinders the neurons ability to produce ATP. Consequently, cells switch to 
anaerobic metabolism which consumes glucose and produces lactic acid. As glucose 
concentrations are exhausted, ion transporters using ATP fail to function. Cells become 
depolarized allowing ions, including calcium, to flow into the cell. Due to the lack of ATPase 
activities, cells cannot pump calcium out of the intracellular space, and as intracellular 
calcium levels rise they trigger the release of excitatory neurotransmitters. Glutamate, one of 
the excitatory neurotransmitters, acts on AMPA and NMDA receptors to allow more 
calcium into cells and thereby increases the intracellular calcium leading to production of 
neurotoxic chemicals such as free radicals, reactive oxygen species and calcium-dependent 
enzyme (Sinclair & Andrews, 2010). This process is referred to as excitotoxicity. Calcium-
dependent enzymes such as calpain, endonucleases, and phospholipases break down cells 
making them more permeable to harmful chemicals and leads to damage of the 
mitochondrial membrane, ultimately causing release of pro-apoptotic factors that stimulate 
the caspase cascade and inducing cell suicide. Cells that die due to necrosis cause a release 
of glutamate and other neurotoxic compounds that act on surrounding cells and perpetuate 
excitotoxicty.  
Hypothermia exerts its effect on the ischemic cascade mentioned above to improve 
neurologic outcome after cardiac arrest. The following discussion will elaborate on mild 
therapeutic hypothermia and how it mitigates the pathologic processes involving: 1) blood-
brain barrier permeability and edema, 2) inflammation, 3) metabolism, 4) excitotoxicity, 5) 
intracellular calcium-dependent signaling 6) cerebral vascular effects, and 7) neuronal cell 
death. 
3.1 Blood-brain barrier permeability and edema 
The blood-brain barrier displays increased permeability after ischemia and allows the 
entrance of water, electrolytes, and potentially toxic substances into the brain 
parenchyma. Hypothermia has been shown to decrease the extravasation of certain 
protein markers such as horseradish peroxidase from the serum into the brain. Studies 
have also demonstrated that treatment with hypothermia in focal ischemia results in a 
decrease in brain water content as measured by MRI, and leads to a reduction in the 
diffusion of water into the brain and a consequent reduction in vasogenic edema by 
alleviating blood-brain barrier injury (Sinclair & Andrews, 2010). Vasogenic edema is a 
result of damage to the blood-brain barrier and the passage of large osmotically-active 
proteins like albumin into the brain. 
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The attenuation of matrix metalloproteases is another effect of hypothermia that reduces the 
permeability of the blood-brain barrier. Matrix metalloproteases are important for the 
extravasation of several substances into the brain including immunologic and other 
inflammatory cells. Reducing movement of these cells into the brain decreases deleterious 
edema associated with inflammatory immune responses to ischemia and neuronal cell 
injury. 
3.2 Inflammation and immune response 
Hypothermia mitigates the inflammation response by reducing the leukocyte extravasation 
as well as the endogenous inflammatory response of the brain to ischemia. Astrocytes and 
microglia respond to tissue damage in the brain by proliferating and secreting large 
quantities of pro-inflammatory cytokines such as tumor necrosis factor-ǂ and interleukin-1 
which recruit cells of the immune system. Hypothermia reduces the activation of astrocytes 
and microglia thereby reducing the pro-inflammatory signaling and the ensuing immune 
response (Sinclair & Andrews, 2010). 
The inflammatory response in the brain also results in the release of reactive oxygen species 
by astrocytes and microglia. Hypothermia, therefore, also reduces the levels of potentially 
damaging free radicals such as superoxide, nitric oxide, and hydroxyl radicals within the 
brain by decreasing their secretion from microglia and astrocytes. Hypothermia also 
increases the levels of superoxide dismutase, the enzyme that clears superoxide from the 
body, and decreases nitric oxide synthase, the enzyme responsible for production of nitric 
oxide. This reduction in reactive oxygen species production and increase in reactive oxygen 
species scavenger enzymes results in decreased neuronal damage.  
3.3 Metabolism 
Hypothermia has been proven to decrease glucose utilization. Studies implementing 2-
deoxyglucose, a glucose analog that can be taken up by glucose transporters but not 
digested, has shown that hypothermia decreases utilization of glucose when compared to 
normothermia. Global ischemia affects the brain more than the liver due to the small stores 
of glycogen found in the brain compared to large stores found in the liver. Therefore, any 
reduction in glucose utilization will attenuate the damaging effects of poor cerebral 
perfusion. Hypothermia reduces the metabolic demands of the cell, preserving cellular ATP 
concentration more effectively when compared to normothermia. Reducing core 
temperature 1°C decreases metabolic rate by approximately 6%-8% (Adler et al, 2011). 
The cell’s ability to maintain electrochemical gradients depends heavily upon ATP 
concentrations. Loss of transmembrane electrochemical gradients directly precedes failure of 
synaptic transmission and axonal conduction. Hypothermia’s ability to reduce metabolic 
demands, preserve ATP, and potentiate electrochemical gradients translates to better 
neurologic outcomes after recovery from cardiac arrest.  
3.4 Excitotoxicity 
The metabolic depletion of ATP associated with ischemia in cardiac arrest results in an 
inappropriate release of excitatory neurotransmitters such as glutamate. A reduction in the 
blood flow to the brain allows levels of glutamate to build up in the extracellular space 
around neurons. This rise in glutamate leads to activation of glutamatergic receptors AMPA 
(alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) and NMDA (N-methyl d-
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aspartate). Glutamate acts through AMPA and NMDA to produce an influx of calcium from 
the extracellular fluid to the intracellular fluid. This inflow of calcium can injure the cell by 
initiating several cascades within the cell including, free radical generation, mitochondrial 
injury, and ultimately apoptosis (Nolan et al, 2008). Hypothermia inhibits the release of 
glutamine and dopamine while also inducing neurotrophic factors that further reduce 
glutamine release. 
3.5 Intracellular calcium-dependent signaling 
Global ischemia leads to an increase in intracellular calcium, thereby affecting normal 
signaling protein kinases in the cell. Proteins such as calmodulin-dependent kinase II 
(CaMKII) and protein kinase C (PKC) are rescued by hypothermia (Sinclair & Andrews, 
2010). These proteins, as well as other signaling factors, are temperature-sensitive. 
Controlling signaling factors and proteins such as CaMKII and PKC through hypothermia 
influences neuronal injury and normal cell signaling. 
3.6 Cerebral vascular and cellular effects 
Hypothermia affects secretion of vasoactive substances such as endothelin, thromboxane A2, 
and prostaglandin I2 in the brain. Endothelin and thromboxane A2 have vasoconstrictive 
effects while prostaglandin I2 is a vasodilator. Thromboxane A2, endothelin, and 
prostaglandin I2 mediate vascular homeostasis in the brain; during ischemic and traumatic 
events homeostatic balance is shifted towards vasoconstriction, hypoperfusion, and thrombus 
formation. Hypothermia has been shown in animal models and small clinical studies to alter 
the response to injury by attenuating the vasconstrictive response. However, regulation of 
cerebral perfusion is complex and dependent on several factors including the presence or 
absence of cerebral autoregulation, ventilator settings, serum blood gas levels, systemic blood 
pressure, osmotic therapy, etc (Sinclair & Andrews, 2010). 
Necrosis and apoptosis are the result of prolonged tissue ischemia and can be influenced by 
hypothermia. Several gene families associated with apoptosis are temperature-sensitive. 
Brain cells can sense irreversible injury and begin the process of self-destruction. 
Hypothermia leads to a delayed response of the cell to injury and this slowed response is 
mediated by a delay in genetic regulation (Sinclair & Andrews, 2010). Ultimately, 
hypothermia slows secondary injury and apoptosis through delaying the cells initial 
reaction to damage. Apoptosis occurs over the time frame of hours-to-days making 
hypothermia a major factor in mitigating apoptosis during the post-resuscitation phase. 
4. Cooling methods 
Several different cooling techniques are available for use in therapeutic hypothermia; 
however, all of the various techniques fall into two general categories: surface cooling and 
core cooling. Surface cooling can be carried out in two ways; the first utilizes pre-cooled 
pads while the second makes use of heat-exchanging mattresses or pads. Surface cooling 
was used in the two hallmark clinical trials carried out in 2003 in Europe and Australia that 
first demonstrated the beneficial effects of hypothermia on witnessed cardiac arrest 
survivors (Bernard et al, 2003; Holzer & Sterz, 2003). 
Core cooling can be achieved with the use of intravascular cooling catheters filled with cold 
saline or by intravenous injection of cold fluids. Devices for core cooling and surface cooling 
have been specifically designed for use in therapeutic hypothermia but the ultimate goal, 
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whether using either surface or core cooling methods, is to rapidly cool the patient and 
maintain a stable temperature between 32-34°C for at least 24 hours. 
Various measurements and devices may be used to monitor relevant core body 
temperature including esophageal probes, endotracheal tube cuff monitors, and non-
invasive continuous cerebral temperature monitoring (Zeiner et al, 2010; Haugk et al, 
2010). During the initial phase of head and neck cooling, jugular bulb temperature (Tjb), 
(which may reflect brain temperature) appears to be lower than esophageal temperature 
(Wandaller et al, 2009). 
4.1 Surface cooling 
4.1.1 Ice packs 
Ice packs are an inexpensive and easy technique to initiate cooling. However, they can be 
messy and less effective at cooling and maintaining target temperature. Ice packs can be 
placed all over the body, but are more effectively placed in anatomic areas that have large 
heat-exchange capability due to their blood flow. These areas include the head, neck, axillae, 
and groin. The average temperature drop attained by using ice packs is between 0.03-0.98°C 
per hour (Adler et al., 2011). 
4.1.2 Blankets or surface heat-exchange devices 
Conventional surface cooling blankets are not ideal because of poor surface contact with the 
patient’s skin. Generally, water-circulating cooling devices and ice packs used in 
combination can be effective at rapidly cooling patients. Many clinical studies have used this 
combination as their cooling technique. The patient is sandwiched between two blankets or 
cooling devices and ice packs are then applied. Once target temperature is achieved, the ice 
packs are removed and the blanket or cooling devices are used alone to maintain the target 
temperature. Newer cooling devices, specific for use in therapeutic hypothermia, use an 
adhesive gel to facilitate heat exchange that make them more effective at obtaining and 
maintaining target temperature. 
Weihs and coworkers (2011) used adult, human-sized pigs to study the importance of 
surface area for the cooling efficacy of mild therapeutic hypothermia. Each of five adult, 
human-sized pigs (88-105 kg) was randomly cooled in three phases with pads that covered 
different areas of the body surface corresponding to humans (100% or 30% [thorax and 
abdomen] or 7% [neck]). The cooling pads were effective and safe for rapid induction of 
mild hypothermia in these porcine simulators. depending on the percentage of body surface 
area covered. Extrapolating to humans, covering only the neck, chest, and abdomen may 
achieve satisfactory cooling rates. 
Convective-immersion surface cooling using a continuous shower of 2 degrees C water 
(ThermoSuit System) has also been found to be a rapid, effective method of inducing 
therapeutic hypothermia (Howes et al, 2010) and demonstrated improvement in survival 
and neurologic outcome in swine compared to normothermia (Weihls et al, 2008).  
4.1.3 Cooling helmet 
Helmet cooling devices are also available and have been used in some clinical trials. These 
helmets contain a solution of glycerol that facilitates heat exchange. Although this method is 
effective in cooling the brain it is much slower at reducing overall body temperature when 
compared to other methods. 
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4.2 Core cooling 
4.2.1 Catheter-based technologies 
Catheter-based technologies are usually placed in the femoral vein and provide heat 
exchange between the cooled saline that passes through a large coil in the catheter and the 
blood. The coiling provides a mechanism to increase surface area, thereby increasing the 
heat exchange between blood passing over the catheter. Internal cooling and rewarming is 
much faster and superior to other techniques in tightly regulating target temperature; it is 
possible to cool patients by 1.46°C - 1.59°C per hour (Jacobshagen et al, 2010). A potential 
advantage of using catheter-based cooling combined with anxiolytics is that it may avoid 
the need to use paralytics to decrease the shiver seen in surface cooling techniques.  
4.2.2 Cold fluid infusion 
Several studies have made use of intravenous cold fluid infusion for the induction of 
hypothermia. The rates of infusion differ between studies but the overall outcome is rapid 
cooling of the patient. Cold fluid infusion is a means of inducing hypothermia and cannot be 
used in the long-term maintenance of hypothermia. Usually, cold fluid infusions are used in 
conjunction with surface cooling methods to regulate and maintain patient body 
temperature. Most studies have used either normal saline or lactated Ringer solution as their 
cooling fluids. Evidence from reports using cold fluid infusion have not been associated 
with increased venous pressure, left atrial filling pressures, pulmonary pressures, 
pulmonary edema, cardiac arrhythmia, or other major complications. 
 
Categories of 
Cooling 
Techniques of 
Cooling 
Advantages Disadvantages 
Surface 
Cooling 
Ice packs 
Inexpensive can be 
implemented very quickly. 
Slow rate of cooling and provides 
poor regulation of target 
temperature. 
Cooling blankets 
and surface heat-
exchange devices 
Fair regulation of target 
temperature once it is 
obtained. 
Slow rate of cooling unless used in 
conjunction with other techniques.  
Cooling helmet 
Fair regulation of target 
temperature once it is 
obtained. 
Slowest rate of cooling among 
techniques unless used in 
conjunction with other cooling 
methods. 
Core Cooling 
Catheter-based 
technologies 
Rapid rate of cooling, tight 
target temperature regulation, 
minimize shiver and possible 
avoidance of paralytic usage. 
Increased chance of thrombus 
formation 
Infusion of cold 
fluids 
Rapid rate of cooling 
Poor regulation of target 
temperature 
Table 1. Cooling Technique Summary 
5. Clinical evidence and uses 
5.1 Clinical studies 
The abovementioned landmark clinical trials from Europe and Australia, respectively, in 
2003 established the benefits of hypothermia and have served as the basis for subsequent 
therapeutic hypothermia guidelines and clinical trials. Most clinical trials evaluate the 
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benefits of hypothermia by scoring patients on the CPC Scale, a tool that rates a patient’s 
neurologic status, or by measuring survival rates. 
The European trial enrolled 275 patients whose cardiac arrest was caused by ventricular 
fibrillation or pulseless ventricular tachycardia. Patients were randomly assigned to either 
hypothermic (n = 137) or normothermic (n = 138) groups. Hypothermic subjects were cooled 
to between 32-34°C for 24 hours with a cold air mattress. The primary endpoint of this study 
was to establish a favorable neurologic outcome in patients six months after cardiac arrest. 
The authors found that 55% of surviving hypothermic patients had a favorable neurologic 
outcome, as defined by a score of 1 or 2 on the CPC Scale, compared to 39% of surviving 
normothermic patients. A secondary endpoint was to evaluate complications within the first 
seven days after cardiac arrest, and mortality rate at six months. The European study 
demonstrated that neurologic outcome, as well as patient survival at six months (55% vs. 
41%), both significantly improved in the hypothermic group as compared to the 
normothermic group (Holzer, 2002). 
In the Australian trial, 77 comatose cardiac arrest survivors with ventricular fibrillation or 
pulseless ventricular tachycardia as the initial rhythm were similarly assigned to 
normothermic (n = 34) or hypothermic (n = 43) groups based on randomization. The 
hypothermic group was cooled to 33°C with ice packs for 12 hours and showed a 49% 
survival with favorable neurologic outcome (i.e., discharged home or to a rehabilitation 
facility, with no or moderate disability ), while the normothermic group had a 26% survival 
with favorable neurologic outcome at hospital discharge (Bernard et al, 2002).  
In 2009, Arrich and colleagues performed a Cochrane systematic review and meta-analysis 
to assess the effectiveness of therapeutic hypothermia in patients after cardiac arrest. 
Neurologic outcome, survival and adverse events were the main outcome parameters. The 
authors included all randomized controlled trials assessing the effectiveness of the 
therapeutic hypothermia in patients after cardiac arrest without language restrictions. 
Studies were restricted to adult populations cooled with any cooling method applied within 
six hours of cardiac arrest. Four trials and one abstract reporting on 481 patients were 
included in the systematic review. Quality of the included studies was good in three out of 
five included studies. For the three comparable studies on conventional cooling methods all 
authors provided individual patient data. With conventional cooling methods patients in 
the hypothermia group were more likely to reach a best cerebral performance category score 
of 1 or 2 (CPC, 5-point scale; 1 -- good cerebral performance, to 5 -- brain death) during 
hospital stay (individual patient data; RR, 1.55; 95% CI 1.22 to 1.96) and were more likely to 
survive to hospital discharge (individual patient data; RR, 1.35; 95% CI 1.10 to 1.65) 
compared to standard post-resuscitation care. Across all studies, there was no significant 
difference in reported adverse events between hypothermia and control. The authors 
concluded that conventional cooling methods to induce mild therapeutic hypothermia seem 
to improve survival and neurologic outcome after cardiac arrest, and their review supports 
the current best medical practice as recommended by the International Resuscitation 
Guidelines. 
Testori and colleagues (2011) retrospectively studied 347 cardiac arrest survivors aged > 
18 years suffering a witnessed out-of-hospital cardiac arrest with asystole or pulseless 
electric activity as the first documented rhythm, for whom hypothermia was induced in 
135 patients. They found that subjects who were treated with mild therapeutic 
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hypothermia at a temperature of 32-34°C for 24 hours were more likely to have good 
neurologic outcomes in comparison to patients who were not treated with hypothermia, 
with an odds ratio of 1.84 (95% confidence interval: 1.08-3.13). In addition, the rate of 
mortality was significantly lower in the hypothermia group (odds ratio: 0.56; 95% 
confidence interval: 0.34-0.93).  
While shortening the delay from spontaneous circulation to hypothermic target temperature 
has been theorized as a way of improving survival and neurologic outcome, randomized 
controlled trials and clinical registries have not shown evidence of whether the time to 
target temperature correlates with neurologic outcome. A recent study has reported that in 
comatose cardiac arrest patients treated with therapeutic hypothermia after return of 
spontaneous circulation, a faster decline in body temperature to the 34°C target appears to 
predict an unfavorable neurologic outcome (Haugk, 2011). Among 588 survivors of cardiac 
arrest managed with therapeutic hypothermia, the median time from restoration of 
spontaneous circulation to reaching a temperature of less than 34°C was 209 minutes 
(interquartile range [IQR]: 130-302) in patients with favorable neurologic outcomes 
compared to 158 minutes (IQR: 101-230) (p < 0.01) in patients with unfavorable neurologic 
outcomes. The adjusted odds ratio for a favorable neurologic outcome with a longer time to 
target temperature was 1.86 (95% CI 1.03 to 3.38, p = 0.04). Whether faster cooling is 
detrimental or patients with more severe neurologic damage show a faster cooling rate has 
to be further evaluated.  
Animal and human studies have suggested that hypothermia impairs renal function. Zeiner 
et al (2004) reported that 24 hours of mild therapeutic hypothermia was associated with a 
delayed improvement in renal function that was not reflected in serum creatinine values, 
and this transient impaired renal function appeared to be completely reversible within 4 
weeks. In trying to determine the  relationship between acute kidney injury on survivors of 
cardiac arrest treated with therapeutic hypothermia we found that the incidence of acute 
kidney injury in patients with a CPS 1 or 2 score was 13.6% compared to 86.4% in patients 
with a CPS score > 2 (p < 0.001) (J. Prior, personal communication). Stage 3 acute kidney 
injury correlated with poor neurologic outcome (p = 0.04) but there was no correlation 
between Stages 1 and 2 and neurologic recovery. A longer duration of cardiac arrest was 
predictive of the subsequent development of acute kidney injury (p = 0.01). In summary, the 
presence of acute kidney injury in survivors of cardiac arrest treated with therapeutic 
hypothermia appears to be associated with poorer neurologic function determined at the 
time of hospital discharge. Acute kidney injury in this population may serve as a marker for 
the severity of anoxic injury incurred during arrest.  
5.2 Indications and contraindications 
5.2.1 Indications  
The AHA has recommended that therapeutic hypothermia is indicated in adult patients 
with out-of-hospital cardiac arrests and who have an initial rhthym of ventricular fibrillation 
or nonperfusing ventricular tachycardia, that are comatose or have a Glasgow coma score < 
8, that are hemodynamically stable, and lack a verbal response. Although these are the 
criteria for which hypothermia is recommended, there are other patients that may benefit 
from therapeutic hypothermia such as post-resuscitation patients having initial rhthyms 
other than ventricular fibrillation or nonperfusing ventricular tachycardia, as well as in-
hospital cardiac arrest patients. 
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 _________________________________________________________________________ 
 
 Survivors of witnessed out-of-hospital cardiac arrest of suspected cardiac origin 
 
 Persons with a Glasgow Coma Scale < 8  
    
 Persons with ventricular fibrillation or non-perfusing ventricular tachycardia 
 (those with other rhythyms such as asystole or electomechanical dissociatrion may  
 also benefit although firm data is lacking) 
  
 Persons who are hemodynamically stable (those in cardiac shock may also benefit 
 although firm data is lacking)  
  
 Consider for survivors of in-hospital cardiac arrest (although firm data is lacking) 
 _________________________________________________________________________ 
* Adapted from Holzer 2010. 
Table 2. Summary of indications for induced therapeutic hypothermia in comatose survivors 
of cardiac arrest.  
5.2.2 Contraindications 
Exclusion criteria for the use of therapeutic hypothermia are based upon increased risks to the 
patient. Studies have reported increased but non-significant increases in risk for the following 
patients: having major surgery within the previous 14 days; having systemic infections or 
sepsis, in a coma which is non-cardiac in origin, having active known bleeding or inherited 
bleeding disorder, being pregnant or terminally ill, those with a do-no-resuscitate (DNR) 
order, or having a tympanic temperature < 30°C upon admission (Oommen & Menon, 2011).  
6. Outcomes 
Various methods have been used to try and determine the likelihood of neurologic recovery 
after cardiac arrest, but no single test is effective in accurately predicting neurologic 
outcome post-resuscitation. Clinical trials have established that combining examinations, 
laboratory tests and accounting for co-morbidities is often more accurate in determining 
neurologic outcome. Precise predictors of neurologic recovery are lacking and seriously 
limit the way clinicians assess patient prognosis, develop appropriate plans of care, and 
counsel family members. Therefore, more clinical studies are required to determine a 
uniform protocol for predicting neurologic outcome. 
6.1 Modalities predicting neurological outcome 
6.1.1 Neurologic examination 
A neurologic examination is a fairly reliable predictor of neurological outcome after cardiac 
arrest. The presence of neurologic function during or immediately after return of spontaneous 
circulation (ROSC) roughly predicts a good neurologic outcome. Conversely, patients with a 
Glasgow Coma motor score of ≤ 2 or absent pupillary or corneal reflex at 72 hours can be 
predicted to have a poor neurologic outcome. The CPC Scale has also been classically used to 
predict patient outcome. Patients with a CPC scale score of 1 and 2 are likely to have good 
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outcomes, while patients scoring 3, 4 or 5 have a significantly higher chance of having a poor 
neurologic outcome or death (Nolan et al, 2008). It is worth noting that the neurologic exam 
and CPC score can be influenced by the physiologic circumstances of the patient such as 
hypotension, shock, and severe metabolic dysfunction. Interventions such as paralytics, 
sedatives, and hypothermia also influence the findings of a neurologic examination and must 
be taken into account. Cranial nerve findings and motor response to pain are the best physical 
features estimating neurologic status and recovery.  
 
1 
Good cerebral performance: conscious, alert, able to work, might have 
mild neurologic or psychologic deficit. 
2 
Moderate cerebral disability: conscious, sufficient cerebral function for 
independent activities of daily life. Able to work in sheltered environment. 
3 
Severe cerebral disability: conscious, dependent on others for daily 
support because of impaired brain function. Ranges from ambulatory state 
to severe dementia or paralysis. 
4 
Coma or vegetative state: any degree of coma without the presence of all 
brain death criteria. Unawareness, even if appears awake (vegetative state) 
without interaction with environment; may have spontaneous eye opening 
and sleep/awake cycles. Cerebral unresponsiveness. 
5 Brain death: apnea, areflexia, EEG silence, etc. 
Note: If patient is anesthetized, paralyzed, or intubated, use “as is” clinical condition to calculate scores. 
Table 3. Cerebral Performance Categories Scale (CPC Scale) 
6.1.2 Neurophysiologic tests 
Electroencephalography (EEG) has been used to characterize the degree of brain damage 
after cardiac arrest. Various EEG patterns have been associated with poor neurologic 
outcome such as generalized suppression, burst-suppression patterns with generalized 
epileptiform activity, and generalized periodic complexes on a flat background. 
Nevertheless, EEG alone is likely to be insufficient to prognosticate neurologic recovery. The 
EEG requires a physician with experience in its interpretation and knowledge of the 
influence of drugs and metabolic disorders on its results.  
Madl & Holzer (2004) reviewed the literature on the pathophysiology of brain injury caused 
by cardiac arrest and the beneficial effect of therapeutic hypothermia on neurologic outcome. 
They summarized that electrophysiologic techniques and molecular markers of brain injury 
allow the accurate assessment and prognostication of long-term outcome in cardiac arrest 
survivors. In particular, somatosensory evoked potentials (SSEPs) appear to have the highest 
prognostic reliability; a systematic review of 18 studies analyzed the predictive ability of SSEPs 
performed early after onset of coma and found that absence of cortical SSEPs identify patients 
not returning from anoxic coma, with a specificity of 100%. Somatosensory-evoked potentials 
test the patency of the neuronal pathways, and are less affected by common drugs and 
metabolic disorders, making them a more reliable predictor of neurologic outcome than other 
modalities (Nolan et al, 2008). However, use of SSEPs in post-resuscitation patients requires 
advanced neurologic training which is usually restricted to specialized centers. 
6.1.3 Neuroimaging 
Neuroimaging is often performed to define structural brain injury related to cardiac arrest 
(either as a cause or consequence), including hemorrhage and cerebral vascular occlusion. 
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Most clinical studies evaluating neurologic outcome after use of therapeutic hypothermia do 
not make use of neuroimaging. The most common type of neuroimaging employed has been 
cranial computed tomography (CT), predominately because of the technical difficulties in 
performing magnetic resonance imaging (MRI) and positron emission tomography (PET) 
scans in the setting of arrest. Limited studies have shown that diffusion-weighted imaging 
(DWI), fluid attenuated inversion recovery (FLAIR), abnormalities in PET, and magnetic 
resonance spectroscopy can help predict poor neurologic outcome (Nolan et al, 2008).  
6.1.4 Biochemical markers 
Biochemical markers derived from the cerebrospinal fluid (CSF) and peripheral circulation, such 
as creatine phosphokinase (CPK) and neuron-specific enolase (NSE) respectively, have been used 
to predict neurologic outcome after cardiac arrest. The ease of obtaining blood compared to CSF 
has favored blood-based biochemical markers. Neuron-specific enolase is easily measured in the 
blood after injury to the brain and is, therefore, a good marker for neurologic outcome. Studies 
have shown that values of NSE > 33µg/L are predictor of poor neurologic outcome.  
A calcium-binding protein from astroglia and Schwann cells, S100ǃ, may also be a marker of 
neurologic outcome. An S100 ǃ concentration > 1.2 µg/L, drawn between 24 and 48 hours 
after ROSC, is indicative of poor neurologic recovery (Nolan et al, 2008). Biomarker 
threshold values established in clinical trials vary based on the time blood and CSF are 
drawn after ROSC and the method for measuring the biomarker. Therefore, standardization 
must be applied in future clinical trials so that true threshold values can be elucidated and 
used to predict patient outcome. 
6.1.5 Co-morbidities 
We previously reported that the risk of poor neurologic outcome among patients treated with 
mild therapeutic hypothermia was related to the number of risk factors present (Table 4) 
(Vanston et al, 2010). A first rhythm of non-ventricular tachycardia/ventricular fibrillation 
after cardiac arrest, acute kidney injury within the first 72 hours of intensive care, and any 
treated cardiac arrhythmia were factors significantly associated with poor neurologic outcome 
and death (Table 4).  
 
 
a CPS. Pittsburgh Cerebral Performance Scale; C.I. = confidence intervals 
b Significantly greater than the risk of poor neurologic outcome amongs patients with no predictive 
factors (p = 0.004). 
c Significantly greater than the risk of poor neurologic outcome amongs patients with no predictive 
factors (p = 0.002). 
d Include first rhythym other than ventricular fibrillation/ ventricular tachycardia, any arrhythmia,  
and acute kidney injury.  
Table 4. Risk of poor neurologic outcome among patient treated with mild therapeutic 
hypothermia, according to number of risk factors present.a 
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6.2 Adverse effects 
Adverse effects of mild induced therapeutic hypothermia are either directly related to the 
cooling device or due to hypothermia itself. In 41 clinical trials using therapeutic 
hypothermia the overall rate of adverse events related to a cooling device was 1% (Holzer, 
2010). These adverse effects included three cases of bleeding, eight cases of infection, ten 
cases of deep venous thrombosis, and eight cases of pulmonary edema. The cases of deep 
venous thrombosis were seen in patients that were cooled with a catheter-based device, 
while the cases of pulmonary edema occurred in patients that were cooled with cold 
intravenous fluid. 
Hypothermia causes a decrease in insulin secretion, as well as insulin resistance in many 
patients. This state of hyperglycemia requires administration of insulin to maintain glucose 
levels within an acceptable range. More importantly, during the re-warming phase patients 
can regain appropriate sensitivity to insulin rapidly, making them susceptible to 
hypoglycemia if insulin administration is not reduced accordingly. Glycemic lability is one 
of several reasons why re-warming rates after hypothermia are typically slow and 
controlled. 
Some of the adverse effects most commonly associated with therapeutic hypothermia 
include pneumonia, shivering hyperglycemia, cardiac arrhythmias, seizures, and electrolyte 
disorders. Less frequently seen complications are sepsis, coagulopathy, and metabolic 
disturbances. Many of these effects can be easily managed by proper patient monitoring. In 
a study compiling data from major clinical trials on adverse effects unrelated to the cooling 
devices, such events occurred in 74% of patients who were treated with hypothermia (223 
events in 300 patients) and in 71% of 285 patients given standard, normothermic treatment 
(Holzer, 2010). The incidences of cardiac arrhythmia, hemodynamic instability, bleeding, 
pneumonia, sepsis, renal failure, seizures, and pancreatitis were not significantly different 
between the two groups. 
7. Slow implementation 
Although its use is becoming more widespread, therapeutic hypothermia is still not 
appropriately initiated for a majority of eligible patients. Concerns with the ease of use, 
efficacy, and cost have limited use in the community setting. The current level of 
implementation of therapeutic hypothermia is difficult to measure, although hypothermia 
registries are attempting to bridge the gap. The AHA, along with some local communities, is 
advocating for the care of all patients with cardiac arrest at centers specializing in post-
arrest care in order to provide the best possible outcomes. Such centers would have the 
capability to perform therapeutic hypothermia, perform percutaneous coronary 
intervention, and utilize standardized protocols for the treatment of cardiac arrest survivors, 
as well as pay close attention to related aspects of overall management including 
hemodynamic stability, ventilator support (with timely normalization of FiO2 and pCO2), 
thromboembolic prophylaxis, and glycemic control. 
8. Ongoing and potential future research  
8.1 Neurologic prognosis 
In patients managed with therapeutic hypothermia clinical research is ongoing regarding 
clinical modeling and the use of aspects of the neurologic exam and acute and chronic 
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medical co-morbidities in predicting neurologic recovery. We have previously found that 
several simple and reproducible clinical markers (i.e., first rhythm at cardiac arrest; the 
presence of acute kidney injury in the ICU; any treated cardiac arrhythmia after admission; 
and Glasgow Coma Score < 8 determined 12 hours after re-warming) can help predict 
neurologic prognosis during and after treatment, in patients managed with therapeutic 
hypothermia for cardiac arrest (Vanston, 2010). Additional investigation is neded to 
examine the potential role of other exam techniques, and electrophysiologic and 
neurobiochemical tests in reliably predicting neurologic outcomes, and to determine the 
correlation between laboratory values or exam scores and time after return of spontaneous 
circulation. 
8.2 Non-shockable rhythms/ other cardiac  
Small randomized trials and registries have begun to collect data on the use of therapeutic 
hypothermia in cardiac arrests with non-shockable rhythms and in-hospital cardiac arrests. 
Recently, in a retrospective cohort study treatment with mild therapeutic hypothermia at a 
temperature of 32-34°C for 24 hours was associated with improved neurologic outcome and 
a reduced risk of death following out-of-hospital cardiac arrest in 135 with non-shockable 
rhythms (Testori et al, 2011). To date, the level of evidence is inadequate to firmly 
recommend therapeutic hypothermia for these patients; nevertheless, many of these patients 
are treated with therapeutic hypothermia in the community if their arrest is thought to be of 
cardiac origin or if the initial rhythm after arrest is unknown. Further research is needed to 
determine the potential role of therapeutic hypothermia for these subsets of patients. The 
ILCOR currectly advocates the use of therapeutic hypothermia following perinatal 
asphyxia-related cardiac arrest in term newborns.  
At least one study (a retrospective analysis of the Hypothermia after Cardiac Arrest 
(HACA) trial) suggested that cooling after successful resuscitation for ventricular fibrillation 
cardiac arrest did not influence infarct size (Koreny et, 2009). The authors contended that 
cautious interpretation of the subgroup analysis may indicate a favorable trend for early 
cooling, and thus additional research is indicated. 
8.3 Non-cardiac applications 
Clinical trials are still revealing further application of therapeutic hypothermia. It is likely 
that recommendations and the use of therapeutic hypothermia will expand to encompass 
several other pathologies such as traumatic brain and spinal cord injury and acute ischemic 
stroke. Currently, therapeutic hypothermia is not approved by an advisory panel for any 
other use besides comatose patients after return of spontaneous circulation due to 
ventricular fibrillation or pulseless ventricular tachycardia (Adler et al, 2011). 
8.4 Aspects of treatment 
Current and potential future areas of clinical research on treatment aspects of therapeutic 
hypothermia include, among others: 
 Optimal target temperature, duration, onset, cooling rates, and re-warming rates 
 Use of external, internal, or mixed modality cooling techniques 
 Pharmacologic uses and standardized drug protocols i.e. (analgesics, sedatives, 
paralytics, etc.) 
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9. Areas of uncertainty 
Some persistent unexposed topics that relate to the pathophysiology of therapeutic 
hypothermia include the precise mechanism(s) of greatest importance for good neurologic 
recovery, the mechanism(s) through which hypothermia exerts the most influence, the 
effects of co-morbidities in reducing the efficacy of therapeutic hypothermia, and the time 
course of cellular cascades and the ability to attenuate these processes (Holzer, 2010). 
10. Guidelines 
Sedation, analgesia, and paralysis should be initiated prior to hypothermia to prevent 
shivering which can increase oxygen consumption, promote labored breathing, increase 
heart rate, delay hypothermic induction, and increase patient discomfort. 
The ILCOR and the AHA recommend that core body temperature of unconscious adult 
patients with spontaneous circulation after an out-of- hospital ventricular fibrillation cardiac 
arrest should be lowered to 32-34°C. The cooling process should be started in the pre-
hospital setting or as soon as possible and continued for 12-24 hours. Core temperature 
should be continuously monitored via the esophagus, rectum, trachea or bladder. General 
management of hypothermia patients includes concurrent measurement of mean arterial 
pressure, central venous pressure, urine output, arterial blood gases, central venous oxygen 
saturation, serum lactate, blood glucose, electrolytes, and complete blood count, and 
continuous ECG monitoring and stabilization.  
After hypothermia, patients should be re-warmed at a rate of 0.5°C per hour with avoidance 
of hyperthermia. Potassium administraction should be stopped to avoid hyperkalemia 
during the re-warming phase. After re-warming to 36°C, sedation and paralytic agents 
should be discontinued and the patient should be weened off ventilator support 
(Jacobshagen et al, 2010). Neurologic recovery can take several hours after discontinuation 
of hypothermia. Therefore, it is important to wait until the patient is completely re-warmed 
and stabile before evaluating patients with prognositic neurologic exams like the Glasgow 
Coma Scale. 
11. Conclusions 
Mild therapeutic hypothermia is indicated for use in witnessed out-of-hospital cardiac arrest 
patients with a return of spontaneous circulation, for persons with an initial rhythm of 
ventricular fibrillation or non-perfusing ventricular tachycardia, for persons who are 
comatose or have a Glasgow coma score < 8, those who are hemodynamically stable, and 
those who lack a verbal response. Clinical evidence has shown that mild hypothermia 
decreases mortality and increases the proportion of patients with a favorable neurologic 
outcome (score of 1 or 2 on the CPC Scale) with mininimal risk of adverse effects. 
Therapeutic hypothermia is a relatively inexpensive treatment modality with an incremental 
cost-effectiveness ratio of $47,168 (Merchant et al, 2009) and can be implemented in a variety 
of settings from rural community-based hospitals to specialized cardiac and neurologic 
centers. The indications for mild therapeutic hypothermia will broaden in the future as more 
clinical trials are conducted. It is important to understand the pathophysiologic processes 
involved in the post-cardiac arrest syndrome, as well as the concominant changes in human 
physiology during induced mild therapeutic hypothermia. 
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